Finding Opportunity in Small Biotech Companies: Five Equities to Watch from 2025

The biotech sector demonstrated resilience throughout 2025 despite broader market volatility. The NASDAQ Biotechnology Index experienced significant growth, climbing from 3,637.05 in October 2023 to reach 4,954.813 by September 2024. After a slight pullback to 4,530.69 in August 2025, the index mounted a notable recovery, finishing the year at 5,766.59—representing approximately 34 percent annual gains. Small biotech companies, particularly those with market capitalizations between $50 million and $500 million, have been among the strongest performers, driven by promising clinical data and innovative therapeutic approaches across oncology, infectious disease, and rare diseases.

Emerging Winners Among Small Biotech Companies: Market Overview

The exceptional performance of small biotech companies in 2025 reflects broader industry trends favoring innovation-driven growth. Investors increasingly focused on companies advancing novel cancer immunotherapies, rare disease treatments, and solutions addressing significant unmet medical needs. The combination of FDA regulatory pathways designed to accelerate development and positive Phase trial data created a compelling investment backdrop for small biotech equities.

As of December 29, 2025, data screening identified several standout performers within the small biotech company segment that warrant closer examination.

SELLAS Life Sciences Group: Advancing Next-Generation Cancer Immunotherapy

Year-to-date performance: 210.19 percent gain
Market capitalization: US$477.18 million
Share price: US$3.35

SELLAS Life Sciences Group operates as a late-stage biopharmaceutical developer focused on harnessing the immune system to combat cancer. The company’s central strategy involves “educating” the immune system to identify and eliminate cancer cells by targeting proteins that are abnormally expressed in tumor tissue.

The company’s principal asset is galinpepimut-S (GPS), a vaccine-like immunotherapy designed for patients with acute myeloid leukemia in remission facing high relapse risk. A secondary candidate, SLS009, represents a selective CDK9 inhibitor showing encouraging Phase 2 results across blood cancers.

Share price momentum accelerated sharply in late December following an update on the Phase 3 REGAL trial evaluating GPS as maintenance therapy for AML patients. The survival-endpoint study, triggered at 80 patient deaths, had recorded 72 deaths by December 26. The extended trial timeline—originally expected to conclude before year-end—has generated investor speculation that trial participants are experiencing significantly extended survival compared to historical benchmarks, potentially indicating meaningful clinical benefit.

IO Biotech: Combining Immunotherapy with Proven Cancer Treatments

Year-to-date performance: 129.47 percent gain
Market capitalization: US$144.28 million
Share price: US$2.16

IO Biotech develops immune-modulating cancer vaccines leveraging its T-win technology platform to activate T cells targeting both tumor cells and immune-suppressive microenvironments. The clinical-stage company’s lead candidate, IO102-IO103 (branded as Cylembio), received FDA breakthrough therapy designation for advanced melanoma treatment when combined with Merck’s Keytruda anti-PD-1 therapy, based on positive Phase 1/2 data.

A pivotal moment arrived in August when the Phase 3 trial readout demonstrated that Cylembio combined with Keytruda achieved 19.4 months of progression-free survival versus 11 months for Keytruda monotherapy—though results narrowly missed statistical significance thresholds. Following December FDA discussions regarding development pathways forward, IO Biotech committed to designing a new registrational trial while pursuing additional funding to sustain operations through 2026. The company continued expanding its pipeline throughout the year, presenting preclinical data in November for IO112 (targeting arginase 1) and IO170 (targeting transforming growth factor).

Tiziana Life Sciences: Intranasal Delivery Platform for Unmet Needs

Year-to-date performance: 124.64 percent gain
Market capitalization: US$184.22 million
Share price: US$1.55

Tiziana Life Sciences represents a clinical-stage developer creating therapies for autoimmune, inflammatory, degenerative, and liver-related conditions. The company’s competitive advantage rests on proprietary intranasal drug delivery technology offering a potential alternative to intravenous administration.

The company’s central development asset is intranasal foralumab, a fully human anti-CD3 monoclonal antibody under evaluation across multiple indications. During 2025, the company advanced foralumab through multiple clinical programs. In March, it submitted an investigational new drug application for a Phase 2 ALS trial, with patient dosing expected to commence in early 2026 under support from the ALS Association. A Phase 2a trial for multiple system atrophy initiated patient dosing in August. Johns Hopkins University and University of Massachusetts launched Phase 2 studies for non-active secondary progressive multiple sclerosis, with May data showing improvements in quality of life measures.

Particularly compelling were Alzheimer’s disease developments. PET imaging from May revealed significant reductions in microglia activation associated with neuroinflammation following three months of treatment. In July, immunologic analysis uncovered unexpected findings suggesting that foralumab may enhance phagocytosis markers in classical monocytes, potentially clearing amyloid plaques and providing dual benefit by addressing both neuroinflammation and amyloid accumulation. Patient enrollment in the randomized Phase 2 Alzheimer’s trial commenced in December. Year-end submission of comprehensive safety documentation to the FDA highlighted over 37 patient-years of treatment without serious drug-related adverse events.

Spero Therapeutics: Addressing Infectious Disease With Unmet Need

Year-to-date performance: 119.05 percent gain
Market capitalization: US$129.58 million
Share price: US$2.30

Spero Therapeutics develops novel treatments for rare diseases and multi-drug resistant bacterial infections representing significant clinical challenges. The company’s lead asset is tebipenem pivoxil hydrobromide, a late-stage oral carbapenem developed collaboratively with pharmaceutical partner GSK to treat complicated urinary tract infections including pyelonephritis.

Regulatory support accelerated development, with the FDA granting qualified infectious disease product and fast-track designations. On May 28, Spero surged 245 percent after announcing that its Phase 3 trial met the primary efficacy endpoint and concluded early based on positive results. This data supported GSK’s December 19 new drug application resubmission to the FDA, triggering a $25 million milestone payment anticipated in Q1 2026.

OKYO Pharma: Innovative Treatment for Neuropathic Corneal Pain

Year-to-date performance: 60.5 percent gain
Market capitalization: US$74.85 million
Share price: US$1.91

OKYO Pharma develops therapies targeting neuropathic corneal pain and dry eye disease through its lead candidate urcosimod, a non-steroidal, non-opioid analgesic designed to address unmet patient needs in ophthalmology.

The company advanced its development program considerably during 2025. After receiving FDA fast-track designation in May following early Phase 2 trial conclusion, OKYO reported robust Phase 2 data in July and received $1.9 million in non-dilutive funding supporting clinical advancement. September activities included announcement of a 120-patient multi-center ascending dose trial designed to establish optimal dosing for Phase 3 registration.

A significant scientific breakthrough emerged on December 11 when imaging data demonstrated that urcosimod may help restore corneal nerve structure, with treatment patients showing median increases in nerve fiber count and length while placebo recipients experienced median decreases in both measures—suggesting a potential novel mechanism of action.

Investment Implications for Small Biotech Companies

The exceptional 2025 performance of these five small biotech companies reflects the sector’s fundamental strength: innovative approaches to serious unmet medical needs supported by advancing clinical evidence. As these companies progress through regulatory pathways and potentially reach commercialization milestones in 2026 and beyond, the investment community continues monitoring small biotech equities for transformative therapies capable of delivering significant returns to early-stage investors who identify winners among the broader small biotech company universe.